Effects of the β-carbolines, harmane and pinoline, on insulin secretion from isolated human islets of Langerhans

被引:43
作者
Cooper, EJ
Hudson, AL
Parker, CA
Morgan, NG
机构
[1] Peninsula Med Sch, Inst Biomed & Clin Sci, Plymouth PL6 8BX, Devon, England
[2] Univ Keele, Sch Life Sci, Cellular Pharmacol Grp, Keele ST5 5BG, Staffs, England
[3] Univ Bristol, Psychopharmacol Unit, Bristol, Avon, England
基金
英国惠康基金;
关键词
efaroxan; beta-cell; insulin secretion; imidazoline-binding site; KU14R; beta-carboline; clonidine-displacing substance;
D O I
10.1016/j.ejphar.2003.09.039
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It is well known that certain imidazoline compounds can stimulate insulin secretion and this has been attributed to the activation of imidazoline I-3 binding sites in the pancreatic beta-cell. Recently, it has been proposed that beta-carbolines may be endogenous ligands having activity at imidazoline sites and we have, therefore, studied the effects of beta-carbolines on insulin secretion. The beta-carbolines harmane, norharmane and pinoline increased insulin secretion two- to threefold from isolated human islets of Langerhans. The effects of harmane and pinoline were dose-dependent (EC50: 5 and 25 muM, respectively) and these agents also blocked the inhibitory effects of the potassium channel agonist, diazoxide, on glucose-induced insulin release. Stimulation of insulin secretion by harmane was glucose-dependent but, unlike the imidazoline I-3 receptor agonist efaroxan, it increased the rate of insulin release beyond that elicited by 20 mM glucose (20 mM glucose alone: 253 +/- 34% vs. basal; 20 mM glucose plus 100 muM harmane: 327 +/- 15%; P < 0.01). Stimulation of insulin secretion by harmane was attenuated by the imidazoline 13 receptor antagonist KU14R (2 (2-ethyl 2,3-dihydro-2-benzofuranyl)-2-imidazole) and was reduced when islets were treated with efaroxan for 18 h, prior to the addition of harmane. The results reveal that beta-carbolines can potentiate the rate of insulin secretion from human islets and suggest that these agents may be useful prototypes for the development of novel insulin secretagogues. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:189 / 196
页数:8
相关论文
共 54 条
[1]  
Atlas D, 1995, Ann N Y Acad Sci, V763, P314, DOI 10.1111/j.1749-6632.1995.tb32417.x
[2]   Agmatine is not a good candidate as endogenous ligand for imidazoline sites of pancreatic B cells and vascular bed [J].
Berdeu, D ;
Puech, R ;
LoubatieresMariani, MM ;
Bertrand, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 308 (03) :301-304
[3]   I1 receptors, cardiovascular function, and metabolism [J].
Bousquet, P .
AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (11) :317S-321S
[4]   Identification and characterization of I1 imidazoline receptors:: Their role in blood pressure regulation [J].
Bousquet, P .
AMERICAN JOURNAL OF HYPERTENSION, 2000, 13 (06) :84S-88S
[5]   Imidazoline receptors in cardiovascular and metabolic diseases [J].
Bousquet, P ;
Dontenwill, M ;
Greney, H ;
Feldman, J .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 :S21-S25
[6]   THE IMIDAZOLINE SITE INVOLVED IN CONTROL OF INSULIN-SECRETION - CHARACTERISTICS THAT DISTINGUISH IT FROM I-1-SITE AND I-2-SITE [J].
CHAN, SLF ;
BROWN, CA ;
SCARPELLO, KE ;
MORGAN, NG .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 112 (04) :1065-1070
[7]   The effect of the putative endogenous imidazoline receptor ligand, clonidine-displacing substance, on insulin secretion from rat and human islets of Langerhans [J].
Chan, SLF ;
Atlas, D ;
James, RFL ;
Morgan, NG .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 (05) :926-932
[8]   Clonidine-displacing substance and irs putative role in control of insulin secretion: A minireview [J].
Chan, SLF .
GENERAL PHARMACOLOGY, 1998, 31 (04) :525-529
[9]   Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan [J].
Chan, SLF ;
Mourtada, M ;
Morgan, NG .
DIABETES, 2001, 50 (02) :340-347
[10]   STIMULATION OF INSULIN-SECRETION BY EFAROXAN MAY INVOLVE INTERACTION WITH POTASSIUM CHANNELS [J].
CHAN, SLF ;
MORGAN, NG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 176 (01) :97-101